Asthma rx, omalizumab, tied to late-onset anaphylaxis.(News)

From: Family Practice News | Date: May 15, 2006| Author: Wendling, Patrice | Copyright information

MIAMI BEACH -- Two patients developed anaphylaxis to the popular allergic asthma medication omalizumab after months of successful treatment, Dr. Kursteen Price reported in a poster at the annual meeting of the American Academy of Allergy, Asthma, and Immunology.

This is the first report of late-onset anaphylaxis to the humanized monoclonal anti-immunoglobulin E (IgE) antibody, she said. According to the prescribing information for omalizumab (Xolair), "anaphylaxis has oc...

Read all of this article with a FREE trial to HighBeam Research

Related newspaper, magazine, and journal articles from HighBeam Research

Late-onset anaphylaxis to omalizumab reported.(News)
Skin & Allergy News ; MIAMI BEACH -- Two patients developed anaphylaxis to the popular allergic asthma medication omalizumab after months of successful treatment, Dr. Kursteen Price reported in a poster at the annual meeting of the American Academy of Allergy, Asthma, and Immunology. This is the first report of
Asthma rx, omalizumab, tied to late-onset anaphylaxis.(News)
Family Practice News ; MIAMI BEACH -- Two patients developed anaphylaxis to the popular allergic asthma medication omalizumab after months of successful treatment, Dr. Kursteen Price reported in a poster at the annual meeting of the American Academy of Allergy, Asthma, and Immunology. This is the first report of
Omalizumab in severe chronic urticaria
Indian Journal of Dermatology, Venereology and Leprology ; Sir, Urticaria patients are usually treated with oral antihistamines and 50% of them respond well to this treatment. However, the other 50% do not respond to antihistamines and need a more aggressive approach. Approximately 40-50% of patients with no apparent cause for their urticaria are believed
Xolair
Formulary ; Omalizumab GENETECH/NOVARTIS/TANOX First biologic approved for the treatment of allergic asthma Omalizumab, a recombinant DNA-derived humanized IgG1[kappa] monoclonal antibody, inhibits the binding of IgE to the high-affinity IgE receptor on the surface of mast cells and basophils. The release of
Omalizumab (rhuMAb-E25)
Formulary ; A recombinant humanized monoclonal antibody for the treatment of refractory asthma ABSTRACT While many factors are associated with the development of asthma, IgE-dependent allergy is a major component of airway inflammation and is very common in patients with asthma. Involvement of inflammatory
Omalizumab (Xolair) for treatment of asthma.(Steps: new drug reviews)
American Family Physician ; Synopsis Omalizumab is a recombinant humanized monoclonal antibody (rhuMAb-E25) labeled for treatment of moderate to severe persistent asthma in persons 12 years or older. (1) Omalizumab is the first biotechnology drug for treatment of allergy-induced asthma. It works by inhibiting binding of IgE
Omalizumab appears effective in patients with poorly controlled allergic asthma
Formulary ; DENVER, COLO-Patients whose asthma was poorly controlled with conventional treatments and who received the investigational anti-immunoglobulin-E drug omalizumab experienced about half the number of asthma deterioration-related incidents as patients who did not receive the add-on medication. Rob
Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma
American Journal of Respiratory and Critical Care Medicine ; IgE plays an important role in allergic asthma. We hypothesized that reducing IgE in the airway mucosa would reduce airway inflammation. Forty-five patients with mild to moderate persistent asthma with sputum eosinophilia of 2% or more were treated with humanized monoclonal antibody against IgE
Omalizumab therapy found to quell symptoms of urticaria, food allergy.(Dermatologic Therapy)(Clinical report)
Skin & Allergy News ; PHILADELPHIA -- Treatment with an antibody to IgE led to improved symptoms in patients with urticaria in two pilot studies and a case series reported at the annual meeting of the American Academy of Allergy, Asthma, and Immunology. The antibody, omalizumab, probably is effective for urticaria
Omalizumab pretreatment may boost immunotherapy's safety.(Clinical Rounds)
Family Practice News ; Keystone, Colo. -- Pretreatment with omalizumab to decrease acute systemic reactions during and after rush immunotherapy is but one of several promising strategies aimed at increasing the safety, convenience, appeal, and utilization of allergen immunotherapy, Dr. Harold S. Nelson said at a meeting